MEDS (TRxADE HEALTH Inc) Company Profit

Corporate emblem and logo of trxadehealth.com (MEDS)

Following a strategy shift, the digital distribution platform of TRxADE HEALTH, Inc. (MEDS) has lost its financial stability and requires reorganization. The company's consolidated profit exhibits volatility, with the current mark standing at -0.09. While the business previously relied on stable B2B marketplace fees, the expansion of free IT services from wholesale behemoths is now exerting significant pressure on the profitability of small pharmacy chains.

TRxADE Health Corp (MEDS) - Company Net Income from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for TRxADE HEALTH (MEDS)

- stock value and consensus price forecast:
Market Price TRxADE Health Corp|MEDS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization TRxADE Health Corp|MEDS - Real Price to Acquire Entire Company
- book capitalization information:
Book Price of a Share TRxADE HEALTH|MEDS - Company Book Value|Market Value to Book Value trxadehealth.com|MEDS - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Ratio TRxADE HEALTH, Inc.|MEDS - Long-Term Debt to Capital|Short-Term Debt to Capital TRxADE HEALTH Inc|MEDS - Company Aggregate Debts|Debt to Book Value Ratio TRxADE Health Corp|MEDS - Company Long-Term Debts|Short-Term Debt TRxADE HEALTH|Intermediate Coverage Ratio trxadehealth.com
- earnings and valuation multiples indicators:
MEDS - Net Profit
Fundamental valuation:TRxADE Health Corp
Brand item of TRxADE HEALTH

The investment attractiveness of TRxADE HEALTH (MEDS) depends on the efficiency of digitizing pharmaceutical procurement, where margin growth correlates directly with the purity of the cash flow. By analyzing the company's financial track record, an investor assesses daily net profit as an indicator of operational resilience, allowing for the identification of hidden systemic failures and an objective determination of the asset value reversal point when searching for the market bottom.

Direct competitors

Company Net Income Veeva Corp (VEEV)|DOCS (Doximity, Inc.) - Net Profit|Company Profit HQY (healthequity.com)|Net Income WAY (Waystar)|Profit After Payment of Taxes CRVL|Company Net Income Privia Health Corp PRVA|Final Profit HURN|CERT: Net Income|OMCL (omnicell.com) - Company Profit|GDRX: Net Profit|Schrodinger Inc (SDGR) - Net Profit|PHR (Phreesia Corp) - Net Profit|Company Profit OMDA (Omada)|Net Profit EVH|HSTM - Company Net Income|Definitive Healthcare Corp. - Net Income|Final Profit CCSI|agilon health Inc - Net Profit|Final Profit ABSI (Absci Bio)|SY: Net Profit|Company Net Income NRC Health (NRC)|SPOK (Spok) - Net Profit|Net Profit OptimizeRx Corp|Company Net Income CPSI (TBRG)|Company Net Income SLP (Simulations Plus Inc.)|SOPHiA GENETICS - Net Income|Profit After Payment of Taxes HCAT (healthcatalyst.com)|CareCloud Corp - Net Profit|Final Profit RSSS (researchsolutions.com)|DLHC (dlhcorp.com) - Net Income|OneMedNet - Final Profit|SCNX (Scienture Holdings Inc) - Net Profit|healthcaretriangle.com (HCTI) - Net Financial Result|Company Net Income iSpecimen Inc. (ISPC)|bullfrogai.com - Company Profit|Net Profit WORX (SCWorx Corporation)|MSPR - Net Income|ICCT: Net Income|Net Financial Result orgenesis.com ORGS|r1rcm.com (RCM) - Company Net Income|Net Income Sharecare Inc.|STRM (Streamline Health Solutions Inc.) - Net Profit|Company Net Income Syra Health, Corp. SYRA|Net Profit AMEH|modeln.com - Company Profit|Company Net Income NextGen Healthcare, Inc. NXGN